Ofloxacin microbiology: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) m (→Microbiology) |
||
| Line 12: | Line 12: | ||
{| | {| | ||
|- | |- | ||
|[[File:OCUFLOX 2.jpg|thumb| | |[[File:OCUFLOX 2.jpg|thumb|850px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 18: | Line 18: | ||
{| | {| | ||
|- | |- | ||
|[[File:OCUFLOX 3.jpg|thumb| | |[[File:OCUFLOX 3.jpg|thumb|850px|left]] | ||
|- | |- | ||
|}<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NOROXIN (NORFLOXACIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36087c76-5da9-4fab-e88f-da1d5a579d8e | publisher = | date = | accessdate = 8 January 2014 }}</ref> | |}<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NOROXIN (NORFLOXACIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36087c76-5da9-4fab-e88f-da1d5a579d8e | publisher = | date = | accessdate = 8 January 2014 }}</ref> | ||
Latest revision as of 23:32, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Microbiology
Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA.
Cross-resistance has been observed between ofloxacin and other fluoroquinolones. There is generally no cross-resistance between ofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides.
Ofloxacin has been shown to be active against most strains of the following organisms both in vitro and clinically, in conjunctival and/or corneal ulcer infections as described in the INDICATIONS AND USAGE section.
 |
The safety and effectiveness of OCUFLOX® ophthalmic solution in treating ophthalmologic infections due to the following organisms have not been established in adequate and well-controlled clinical trials. OCUFLOX® ophthalmic solution has been shown to be active in vitro against most strains of these organisms but the clinical significance in ophthalmologic infections is unknown.
 |
References
- ↑ "NOROXIN (NORFLOXACIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.]". Retrieved 8 January 2014.
Adapted from the FDA Package Insert.